3rd dose of Pfizer vaccine 95.6% effective against Delta — phase 3 trial result

A third dose of the vaccine against COVID-19 developed by Pfizer-BioNTech is 95.6% effective against symptomatic infection, according to a study by the makers published today.

The clinical phase 3 trial with “10,000 participants 16 years of age and older” showed “a relative vaccine efficacy of 95.6 percent against disease during a period when Delta was the prevalent strain,” the companies say in a statement.

Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed